BUZZ-Eyenovia discontinues late-stage eye drug study, shares fall

Reuters11-15 20:56

** Shares of drugmaker Eyenovia fall 52.5% to 16 cents premarket

** Co to discontinue a late-stage study for its experimental drug-device combination after it failed the main goal of slowing the progression of the condition

** Co was testing the drug to treat pediatric progressive myopia that causes near-sightedness in early childhood, which worsens as the person grows

** Says an independent committee reviewed the safety and efficacy data from 252 trial participants and found that the rate of myopia progression was not significantly different between the treatment arm and placebo

** "We plan to terminate the study, review the data more thoroughly, and evaluate next steps"- EYEN

** Says it is evaluating its strategic options, which may include a business combination, reverse merger, asset sales or a combination of those alternatives

** Up to last close, stock was down 83.7% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment